| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer DP Petrylak, CM Tangen, MHA Hussain, PN Lara Jr, JA Jones, ME Taplin, ... New England Journal of Medicine 351 (15), 1513-1520, 2004 | 4637 | 2004 |
| Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients JP Stein, G Lieskovsky, R Cote, S Groshen, AC Feng, S Boyd, E Skinner, ... Journal of clinical oncology 19 (3), 666-675, 2001 | 4326 | 2001 |
| Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer HB Grossman, RB Natale, CM Tangen, VO Speights, NJ Vogelzang, ... New England Journal of Medicine 349 (9), 859-866, 2003 | 2864 | 2003 |
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer JS De Bono, HI Scher, RB Montgomery, C Parker, MC Miller, H Tissing, ... Clinical cancer research 14 (19), 6302-6309, 2008 | 2495 | 2008 |
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative … PJ Loehrer Sr, LH Einhorn, PJ Elson, ED Crawford, P Kuebler, I Tannock, ... Journal of Clinical Oncology 10 (7), 1066-1073, 1992 | 1186 | 1992 |
| American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options LE Schnipper, NE Davidson, DS Wollins, C Tyne, DW Blayney, D Blum, ... Journal of Clinical Oncology 33 (23), 2563-2577, 2015 | 999 | 2015 |
| Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data HI Scher, X Jia, JS de Bono, M Fleisher, KJ Pienta, D Raghavan, G Heller The lancet oncology 10 (3), 233-239, 2009 | 724 | 2009 |
| American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology LE Schnipper, TJ Smith, D Raghavan, DW Blayney, PA Ganz, TM Mulvey, ... Journal of Clinical Oncology 30 (14), 1715-1724, 2012 | 684 | 2012 |
| Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received LE Schnipper, NE Davidson, DS Wollins, DW Blayney, AP Dicker, ... Journal of Clinical Oncology 34 (24), 2925-2934, 2016 | 664 | 2016 |
| Intermittent versus continuous androgen deprivation in prostate cancer M Hussain, CM Tangen, DL Berry, CS Higano, ED Crawford, G Liu, ... New England Journal of Medicine 368 (14), 1314-1325, 2013 | 632 | 2013 |
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial … SB Saxman, KJ Propert, LH Einhorn, ED Crawford, I Tannock, ... Journal of Clinical Oncology 15 (7), 2564-2569, 1997 | 586 | 1997 |
| Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest … M Hussain, CM Tangen, C Higano, PF Schelhammer, J Faulkner, ... Journal of clinical oncology 24 (24), 3984-3990, 2006 | 560 | 2006 |
| Biology and management of bladder cancer D Raghavan, WU Shipley, MB Garnick, PJ Russell, JP Richie New England Journal of Medicine 322 (16), 1129-1138, 1990 | 548 | 1990 |
| Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior … J Bellmunt, H von der Maase, GM Mead, I Skoneczna, M De Santis, ... Journal of Clinical Oncology 30 (10), 1107-1113, 2012 | 513 | 2012 |
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. WM Stadler, T Kuzel, B Roth, D Raghavan, FA Dorr Journal of clinical oncology 15 (11), 3394-3398, 1997 | 425 | 1997 |
| Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer D Kaufman, D Raghavan, M Carducci, EG Levine, B Murphy, J Aisner, ... Journal of Clinical Oncology 18 (9), 1921-1927, 2000 | 333 | 2000 |
| Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16 DP Petrylak, DP Ankerst, CS Jiang, CM Tangen, MHA Hussain, ... Journal of the National Cancer Institute 98 (8), 516-521, 2006 | 327 | 2006 |
| Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline E Basch, DA Loblaw, TK Oliver, M Carducci, RC Chen, JN Frame, ... Journal of Clinical Oncology 32 (30), 3436-3448, 2014 | 303 | 2014 |
| Randomised comparison of procedures for obtaining informed consent in clinical trials of treatment for cancer. RJ Simes, MH Tattersall, AS Coates, D Raghavan, HJ Solomon, H Smartt Br Med J (Clin Res Ed) 293 (6554), 1065-1068, 1986 | 269 | 1986 |
| Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status WM Stadler, SP Lerner, S Groshen, JP Stein, SR Shi, D Raghavan, ... Journal of Clinical Oncology 29 (25), 3443-3449, 2011 | 255 | 2011 |
